# A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT06254950** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 207 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** TAK-279
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06254950
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-29
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-08-04
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06254950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06254950, "A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06254950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*